Shares of Curis Inc. CRIS gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.
Curis, whose lead drug candidate is cancer therapy emavusertib, is “the next Pharmacyclics,” Truist analysts led by Robyn Karnauskas wrote in a report Thursday. Pharmacyclics, maker of game-changing cancer drug Imbruvica, was acquired by AbbVie Inc. ABBV for $21 billion in 2015.
The…
Read the full article here
